Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles

Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles

Mucopolysaccharidosis type II (MPSII) is a lysosomal storage disorder due to the deficit of the enzyme iduronate 2-sulfatase (IDS), which leads to the accumulation of glycosaminoglycans in most organ-systems, including the brain, and resulting in neurological involvement in about two-thirds of the p...

Full description

Bibliographic Details
Main Authors:	Laura Rigon, Marika Salvalaio, Francesca Pederzoli, Elisa Legnini, Jason Thomas Duskey, Francesca D’Avanzo, Concetta De Filippis, Barbara Ruozi, Oriano Marin, Maria Angela Vandelli, Ilaria Ottonelli, Maurizio Scarpa, Giovanni Tosi, Rosella Tomanin
Format:	Article
Language:	English
Published:	MDPI AG 2019-04-01
Series:	International Journal of Molecular Sciences
Subjects:	lysosomal storage disorders mucopolysaccharidosis Hunter syndrome MPS II enzyme replacement therapy nanoparticles PLGA blood-brain barrier central nervous system brain targeting
Online Access:	https://www.mdpi.com/1422-0067/20/8/2014

Similar Items

Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment
by: Francesca D’Avanzo, et al.
Published: (2020-02-01)

Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients
by: Rossella Parini, et al.
Published: (2015-06-01)

Mucopolysaccharidoses: early diagnostic signs in infants and children
by: Cinzia Galimberti, et al.
Published: (2018-11-01)

Ocular features in mucopolysaccharidosis: diagnosis and treatment
by: Alessandra Del Longo, et al.
Published: (2018-11-01)

Therapy-type related long-term outcomes in mucopolysaccaridosis type II (Hunter syndrome) – Case series
by: Mojca Zerjav Tansek, et al.
Published: (2021-09-01)

Enzyme replacement therapy: efficacy and limitations
by: Daniela Concolino, et al.
Published: (2018-11-01)

Genetic Assessment of Mucopolysaccharidosis Type IV and the First Pathological Mutation of c.313A>G in the Iranian Population
by: Seyed Mehdi Shafaat, et al.
Published: (2020-03-01)

Management of Difficult Airway in a Patient with Mucopolysaccharidosis Type II
by: Damla Hanalioğlu, et al.
Published: (2019-08-01)

Mucopolysaccharidosis Type II in the Practice of the Physician
by: I.Y. Vatanskaya, et al.
Published: (2016-09-01)

Mucopolysaccharidosis Type-II with Pathognomonic Skin Appearance: A Case with Pebbling Sign
by: Ayşe Hitay İnan, et al.
Published: (2021-06-01)

Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders.
by: Marika Salvalaio, et al.
Published: (2016-01-01)

Brain‐targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms
by: Hélène FE Gleitz, et al.
Published: (2018-07-01)

Case report of endoprosthesis -Y implantation in severe respiratory failure in the MPSII patient; comparison with literature data
by: Wojciech Gocyk, et al.
Published: (2020-04-01)

Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles
by: Antonietta Vilella, et al.
Published: (2015-06-01)

Síndrome de Hunter Mucopolisacaridosis (II):reporte de un caso
by: Ghunter Paz, et al.
Published: (2011-06-01)

Challenging behavior in mucopolysaccharidoses types I–III and day-to-day coping strategies: a cross sectional explorative study
by: Frederik Hoffmann, et al.
Published: (2020-10-01)

Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS)
by: Karolina M. Stepien, et al.
Published: (2020-05-01)

Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations
by: Rossella Parini, et al.
Published: (2020-04-01)

Development of a fluorometric microtiter plate based enzyme assay for MPS IVA (Morquio type A) using dried blood spots
by: Anirudh J. Ullal, et al.
Published: (2014-01-01)

The factors affecting lipid profile in adult patients with Mucopolysaccharidosis
by: Karolina M. Stepien, et al.
Published: (2017-09-01)

Disease Manifestations in Mucopolysaccharidoses and Their Impact on Anaesthesia-Related Complications—A Retrospective Analysis of 99 Patients
by: Luise Sophie Ammer, et al.
Published: (2021-08-01)

Mucopolisacaridosis (síndrome de Hunter)
by: Xidix Toirac Cabrera, et al.

Producción de anticuerpos policlonales IgG contra la proteina iduronato-2-sulfato sulfatasa y desarrollo de un sistema de detección para IDS humana recombinante.
by: Olga Peña, et al.
Published: (2005-06-01)

The levels of urinary glycosaminoglycans of patients with attenuated and severe type of mucopolysaccharidosis II determined by liquid chromatography-tandem mass spectrometry
by: Ryuichi Mashima, et al.
Published: (2016-06-01)

A case of hunter syndrome and Alder-Reilly anomaly
by: Nour AlMozain, et al.
Published: (2017-01-01)

A rare case of severe Hunter's Syndrome
by: Sharon Vincent, et al.
Published: (2018-01-01)

Nationwide Newborn Screening Program for Mucopolysaccharidoses in Taiwan and an Update of the “Gold Standard” Criteria Required to Make a Confirmatory Diagnosis
by: Chih-Kuang Chuang, et al.
Published: (2021-08-01)

A study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patients
by: Ok Jeong Lee, et al.
Published: (2012-03-01)

Analysis of long-term observations of the large group of Russian patients with Hunter syndrome (mucopolysaccharidosis type II)
by: Alla Nikolaevna Semyachkina, et al.
Published: (2021-03-01)

The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients
by: L Chkioua, et al.
Published: (2020-05-01)

Identification and Functional Characterization of <i>IDS</i> Gene Mutations Underlying Taiwanese Hunter Syndrome (Mucopolysaccharidosis Type II)
by: Hsiang-Yu Lin, et al.
Published: (2019-12-01)

PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study
by: Gina P. Hoyos-Ceballos, et al.
Published: (2020-01-01)

How Not to Miss the Mild Forms of Mucopolysaccharidosis Type I in Patients With Articular Manifestations of the Disease?
by: Natalia V. Buchinskaya, et al.
Published: (2019-01-01)

Cardiac disease as the presenting feature of mucopolysaccharidosis type IIIA: A case report
by: Erlane Marques Ribeiro, et al.
Published: (2014-01-01)

The beta-glucuronidase intracisternal A particle insertion model results in similar overall MPSVII phenotype as the single base deletion model when on the same C57BL/6J mouse background
by: Sean C. Devanney, et al.
Published: (2021-06-01)

The multi-domain responder index: a novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases
by: P. K. Tandon, et al.
Published: (2021-04-01)

Exploiting the Potential of <i>Drosophila</i> Models in Lysosomal Storage Disorders: Pathological Mechanisms and Drug Discovery
by: Laura Rigon, et al.
Published: (2021-03-01)

Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance
by: Mehmet Umut Akyol, et al.
Published: (2019-06-01)

Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry
by: Joseph Muenzer, et al.
Published: (2017-05-01)

Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase
by: Melissa J. Hogan, et al.
Published: (2020-12-01)

Cannot write session to /tmp/vufind_sessions/sess_bbptu8m0n9kk0k9s09bndkot86